RxDoctor Payments Data

Robert Hurst, MD

Internal Medicine · Bloomingdale, ILNPI 1972579142

Payments from drug & device makers

$871in general payments, 2019–2025

Across 45 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$201
  • Amgen$136
  • Lilly USA, LLC$118
  • AstraZeneca$94
  • Otsuka America Pharmaceutical, Inc.$53
  • Boehringer Ingelheim$46
  • plus $222 from 10 others

What the payments were for

  • Food & beverage$871100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$871 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$76,192
Medicare patients
272
Services billed
2,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin138$184,780
TrulicityDulaglutide41$73,843
OzempicSemaglutide28$49,145
EliquisApixaban22$30,194
JanuviaSitagliptin Phosphate25$20,415
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$19,608
XareltoRivaroxaban13$17,882
Spiriva HandihalerTiotropium Bromide20$14,003
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$10,953
Atorvastatin Calcium801$7,516
Breo ElliptaFluticasone/Vilanterol11$7,318
SymbicortBudesonide/Formoterol Fumarate11$6,989
Amlodipine-ValsartanAmlodipine Besylate/Valsartan123$4,345
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$4,137
Amlodipine Besylate571$3,938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$46$184,780138 claims
Lilly USA, LLCTrulicity$118$73,84341 claims
Novo NordiskOzempic$201$49,14528 claims
PfizerEliquis$19$30,19422 claims
GSKTrelegy Ellipta, Breo Ellipta$41$26,92522 claims
Johnson & JohnsonXarelto$13$17,88213 claims
AstraZenecaSymbicort$94$6,98911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Bloomingdale

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →